Studying rare genetic variations in prostate cancer using diverse genetic data
Official title: Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancer
Funded at University of Southern California · NIH-10932197 · Data updated 2026-11-12
This study is looking at how certain rare genetic changes might increase the risk of prostate cancer, using data from different groups of people, to help doctors better understand and treat the disease for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | September 20, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $634,844 |
| NIH project number | 5R01CA276826-02 |
| Project ID | NIH-10932197 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include men with a family history of prostate cancer or those from diverse ancestral backgrounds who may carry rare genetic variations.
✕Less likely to help
Patients without a family history of prostate cancer or those who do not belong to the targeted ancestral groups may not benefit from this research.
What this research studies
This research investigates the genetic factors contributing to prostate cancer by analyzing whole-exome and whole-genome sequencing data from various biobanks and cohorts. The study aims to identify rare genetic variations that may increase the risk of developing prostate cancer, particularly focusing on low-frequency alleles that are often overlooked. By integrating data from multiple ancestries, the research seeks to provide a comprehensive understanding of how these rare variations affect prostate cancer susceptibility and aggressiveness. Patients may benefit from insights that could lead to improved risk assessment and personalized treatment options based on their genetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to better understanding and management of prostate cancer risk, potentially improving outcomes for patients.
How similar studies have gone: Previous research has shown promise in identifying genetic variations linked to cancer risk, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Haiman, Christopher Alan — University of Southern California
- Study coordinator: Haiman, Christopher Alan
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.